Comparative study of biochemical and morphological parameters in rats with Walker 256 and Walker 256/DOX carcinosarcoma

Authors

  • L.A. Yushko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V.V. Sarnatskaya R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • L.A. Sakhno R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.V. Hudenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • L.M. Paziuk Taras Shevchenko National University of Kyiv
  • V.N. Maslenny R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V. O. Melnyk National Cancer Institute
  • V.G. Nikolaev R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15636

Keywords:

doxorubicin, drug resistance, Walker 256 and 256/DOX carcinosarcoma

Abstract

Aim: To evaluate the changes of some biochemical blood plasma parameters and morphological structure of the internal organs of rats with transplanted doxorubicin (DOX)-sensitive (Walker 256) and doxorubicin-resistant (Walker 256/DOX) strains of Walker 256 carcinosarcoma. Materials and Methods: The study was performed on female Wistar rats with transplanted Walker 256 or Walker 256/DOX and intact animals (control). On the 9th day after transplantation of tumor cells, a comparative analysis of some blood plasma biochemical parameters and morphological examination of the liver, kidneys, myocardium and spleen of rats was carried out. Results: Walker 256 growth, in comparison with Walker 256/DOX, is accompanied by more pronounced systemic effect on tumor-bearing rats. Uric acid concentration in the blood plasma of Walker 256 bearing rats was significantly (by 15.5%) higher than in Walker 256/DOX bearing rats. Aspartate aminotransferase activity in the Walker 256 group was significantly (by 107.2%) higher than in Walker 256/DOX group, but alanine aminotransferase activity was 58.5% lower. 56.7% decrease of alkaline phosphatase in rats with Walker 256, and 21% increase of this index in rats with Walker 256/DOX were observed. The growth of Walker 256 carcinosarcoma led to greater structural damage of the liver, kidneys and spleen in experimental animals compared with Walker 256/DOX strain. Conclusion: Tumor growth in rats with Walker 256/DOX leads to less pronounced changes in the biochemical parameters of rat blood plasma and morphological structure of internal organs compared with wild-type carcinosarcoma.

References

Mamedov M. The systemic effect of a malignant tumor on organism as a basis for cancer pathogenesis. Biomedicina 2007; 1: 3–10 (In Russian).

McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014; 16: 717–27.

Shenoy PA, Kuo A, Vetter I, et al. The Walker 256 breast cancer cell-induced bone pain model in rats. Front Pharmacol 2016; 7: 1–13.

Nadeev AP, Alekseev AY, Pozdnyakova SV, et al. Morphological assessment of antineoplastic and anti-metastatic efficiency of junggar akonit in experiment. SBEI HPE «Novosibirsk State Medical University of Ministry of Health» 2014; 34: 1–9 (in Russian).

Guaitani A, Recchia M, Carli M, et al. Walker carcinoma 256: A model for studies on tumor-induced anorexia and cachexia. Oncology 1982; 39: 173–8.

Lee Y-H, Govinda B, Kim J-C, et al. Oxidative stress resistance through blocking Hsp60 translocation followed by SAPK/JNK inhibition in aged human diploid fibroblast. Cell Biochem Funct 2008; 26: 320–8.

Vido AA, Cavalcano TC, Guimarães F, et al. The hemolytic component of cancer anemia: Effects of osmotic and metabolic stress on the erythrocytes of rats bearing multifocal inoculations of the Walker 256 tumor. Braz J Med Biol Res 2000; 33: 815–22.

Freitas JJS, Pompéia C, Miyasaka CK, et al. Walker-256 tumor growth causes oxidative stress in rat brain. J Neurochem 2001; 77: 655–63.

Guarnier FA, Cecchini AL, Suzukawa AA, et al. Time course of skeletal muscle loss and oxidative stress in rats with walker 256 solid tumor. Muscle Nerve 2010; 42: 950–8.

Rettori O, Vieira-Matos AN, Gontijo JAR. Re-assessment of the renal hydrosaline dysfunction in rats bearing the Walker-256 tumor. Ren Fail 2000; 22: 769–84.

Kunts TA, Efremov AV, Ovsyanko EV, et al. Dynamics of morhpofunctional characteristics of liver lobule vascular system in Walker 256-bearing rats with carcinosarcoma. Bull SB RAMS 2013; 33: 5–9 (in Russian).

Ramos SG, Soares FA, Bestetti RB, et al. Cardiomyopathy in rats with walker 256 tumor: The potential role of microvascular disease in its genesis. Cardiovasc Pathol 1996; 5: 39–46.

Jian-gang L, Da-wu Z, Lei Z, Dazhuo S. Walker 256 sarcoma stimulates myocardial angiogenesis after acute myocardial infarction. J Clin Exp Cardiol 2015; 6: 6–11.

Russell RR, Alexander J, Jain D, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol 2016; 23: 856–84.

Jain D, Ahmad T, Cairo M, Aronow W. Cardiotoxicity of cancer chemotherapy: Identification, prevention and treatment. Ann Translat Med 2017; 5: 1–12.

Christowitz C, Davis T, Isaacs A, et al. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer 2019; 19: 1–10.

Todor IN, Lukianova NY, Shvets YV, et al. Metabolic changes during development of Walker-256 carcinosarcoma resistance to doxorubicin. Exp Oncol 2015; 37: 19–22.

Chekhun VF, Lozovska YV, Burlaka AP, et al. Metalloproteins during development of Walker-256 carcinosarcoma resistant phenotype. Ukr Biochem J 2015; 87: 103–12.

Sarnatskaya VV, Yushko LA, Prokopenko IV, et al. Structural changes of serum albumin in response to oxidative stress caused by Walker-256 carcinosarcoma growth. Exp Oncol 2020; 42: 40–5.

Pani A, Porta C, Cosmai L, et al. Glomerular diseases and cancer: evaluation of underlying malignancy. J Nephrol 2016; 29: 143–152.

Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dialysis Transplant 2013; 28: 2221–8.

Srivastava A, Kaze AD, McMullan CJ et al. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 2018; 71: 362–70.

Rahimi-Sakak F, Maroofi M, Rahmani J, et al. Serum uric acid and risk of cardiovascular mortality: A systematic review and dose-response meta-analysis of cohort studies of over a million participants. BMC Cardiovasc Disord 2019; 19: 1–8.

Kain V, Kumar S, Puranik AS, et al. Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc Diabetol 2010; 9: 1–9.

Zhang W, Iso H, Murakami Y, et al. Serum uric acid and mortality form cardiovascular disease: EPOCH-JAPAN study. J Atheroscler Thromb 2016; 23: 692–703.

Kleber ME, Delgado G, Grammer TB, et al. Uric acid and cardiovascular events: A Mendelian randomization study. J Am Soc Nephrol 2015; 26: 2831–8.

Sharma U, Pal D, Prasad R. Alkaline phosphatase: An overview. Ind J Clin Bochem 2014; 29: 269–78.

Lum G. Significance of low serum alkaline phosphatase activity in a predominantly adult male population. Clin Chem 1995; 41: 515–8.

Agudelo D, Bourassa P, Bruneau J, et al. Probing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albumins. PLoS One 2012; 7: e43814.

Downloads

Published

26.05.2023

How to Cite

Yushko, L., Sarnatskaya, V., Sakhno, L., Hudenko, N., Paziuk, L., Maslenny, V., … Nikolaev, V. (2023). Comparative study of biochemical and morphological parameters in rats with Walker 256 and Walker 256/DOX carcinosarcoma. Experimental Oncology, 43(1), 21–25. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-1.15636

Issue

Vol. 43 No. 1 (2021): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.